Results 61 to 70 of about 7,553 (206)

Bruton's tyrosine kinase (Btk) associates with protein kinase C μ [PDF]

FEBS Letters, 1999
Bruton's tyrosine kinase (Btk) is considered an essential signal transducer in B‐cells. Mutational defects are associated with a severe immunodeficiency syndrome, X‐chromosome linked agammaglobulinemia (XLA). Here we show by coimmunoprecipitation that a member of the protein kinase C (PKC) family, PKCμ, is constitutively associated with Btk.
Johannes, Franz-Josef, Hausser, Angelika, Storz, Peter, Truckenmüller, Lars, Link, Gisela, Kawakami, Toshiaki, Pfizenmaier, Klaus   +6 more
openaire   +2 more sources

Targeting Solid Tumors With BTK Inhibitors

Frontiers in Cell and Developmental Biology, 2021
The repurposing of FDA-approved Bruton’s tyrosine kinase (BTK) inhibitors as therapeutic agents for solid tumors may offer renewed hope for chemotherapy-resistant cancer patients.
Fatih M. Uckun, Taracad Venkatachalam
doaj   +1 more source

Micro RNA 145 targets the insulin receptor substrate-1 and inhibits the growth of colon cancer cells [PDF]

, 2007
The insulin receptor substrate-1 (IRS-1), a docking protein for both the type 1 insulin-like growth factor receptor (IGF-IR) and the insulin receptor, is known to send a mitogenic, anti-apoptotic, and anti-differentiation signal. Several micro RNAs (miRs)
Baserga, Renato, deAngelis, Tiziana, Linsley, Peter, Prisco, Marco, Sepp-Lorenzino, Laura, Shi, Bin   +5 more
core   +2 more sources

A novel reverse transduction adenoviral array for the functional analysis of shRNA libraries [PDF]

, 2008
Background The identification of novel drug targets by assessing gene functions is most conveniently achieved by high-throughput loss-of-function RNA interference screening.
Angelika Oehmig, Andrea Klotzbücher, Maria Thomas, Frank Weise, Ursula Hagner, Ralf Brundiers, Dirk Waldherr, Andreas Lingnau, Achim Knappik, Michael HG Kubbutat, Thomas O Joos, Hansjürgen Volkmer   +11 more
core   +1 more source

Bruton’s Tyrosine Kinase Inhibition Promotes Myelin Repair

Brain Plasticity, 2019
Background: Microglia are the resident macrophages of the central nervous system (CNS). In multiple sclerosis (MS) and related experimental models, microglia have either a pro-inflammatory or a pro-regenerative/pro-remyelinating function. Inhibition of Bruton’s tyrosine kinase (BTK), a member of the Tec family of
Martin, Elodie, Aigrot, Marie-Stéphane, Grenningloh, Roland, Stankoff, Bruno, Lubetzki, Catherine, Boschert, Ursula, Zalc, Bernard   +6 more
openaire   +3 more sources

A Phase I/II first-line study of R-CHOP plus B-cell receptor/NF-κB-double-targeting to molecularly assess therapy response [PDF]

, 2019
The ImbruVeRCHOP trial is an investigator-initiated, multicenter, single-arm, open label Phase I/II study for patients 61-80 years of age with newly diagnosed CD20+ diffuse large B-cell lymphoma and a higher risk profile (International Prognostic Index ...
Anagnostopoulos, Ioannis, Bittner, Aitomi, Denker, Sophy, Frick, Mareike, Hummel, Michael, Kase, Julia, Na, Il-Kang, Schmitt, Clemens A.   +7 more
core   +2 more sources

Advancements in research on the cardiovascular toxicity caused by TEC family kinases inhibitors

Frontiers in Pharmacology
The tyrosine kinase expressed in hepatocellular carcinoma (TEC) family kinases (TFKs) are a subfamily of non-receptor protein tyrosine kinases (PTKs) that include five members: TEC, bruton’s tyrosine kinase (BTK), interleukin 2-inducible T-cell kinase ...
Yi Zhang, Huangxi Fu, Xingchen Kang, Zixuan Qiu, Hao Yan, Qiaojun He, Qiaojun He, Qiaojun He, Bo Yang, Bo Yang, Bo Yang, Zhifei Xu, Peihua Luo, Peihua Luo   +13 more
doaj   +1 more source

Advances in Bruton tyrosine kinase (Btk) inhibition are steered by Bruton tyrosine kinase phylogeny

British Journal of Pharmacology
AbstractBruton tyrosine kinase (Btk) has long been known to play a key role in chronic lymphatic leukaemia, Waldenström macroglobulinaemia and other B‐cell proliferative disorders. An impressive programme of drug discovery and clinical development led to the approval of covalent and non‐covalent Btk inhibitors that became pillars of treatment of such ...
Minotti, Giorgio, Camilli, Massimiliano, Salvatorelli, Emanuela, Menna, Pierantonio   +3 more
openaire   +3 more sources

Targeting Bruton’s tyrosine kinase (BTK) as a signaling pathway in immune-mediated diseases: from molecular mechanisms to leading treatments

Advances in Rheumatology
Bruton’s tyrosine kinase (BTK), a nonreceptor tyrosine kinase, plays a remarkable role in the transmission and amplification of extracellular signals to intracellular signaling pathways.
Gita Manzari Tavakoli, Niloufar Yazdanpanah, Nima Rezaei   +2 more
doaj   +1 more source

Ibrutinib‐induced severe liver injury

Clinical Case Reports, 2017
Key Clinical Message Ibrutinib, an inhibitor of the Bruton's tyrosine kinase of the B‐cell receptor pathway, is an effective therapeutic agent for B‐cell lymphomas. As these drugs are novel, long‐term or rare adverse events are not yet known.
Amara G. Nandikolla, Olga Derman, Deborah Nautsch, Qiang Liu, Hatef Massoumi, Sangeetha Venugopal, Ira Braunschweig, Murali Janakiram   +7 more
doaj   +1 more source